Buprenorphine is used in opioid use disorder (OUD) maintenance therapy. Which pharmacological property explains why buprenorphine has a 'ceiling effect' for respiratory depression but not necessarily for analgesia?

• A Buprenorphine is a full agonist at mu-opioid receptors but a full antagonist at kappa receptors
• B Buprenorphine's slow dissociation from mu receptors prevents the rapid concentration-dependent depression needed for respiratory arrest
• C Buprenorphine's active metabolite norbuprenorphine blocks respiratory mu receptors selectively
• D Buprenorphine is a partial agonist at mu-opioid receptors; at lower receptor occupancy analgesic responses are obtainable, but respiratory depression requires higher occupancy which plateaus due to partial efficacy ✓

Explanation

Buprenorphine is a partial agonist at mu-opioid receptors (high affinity, low intrinsic efficacy). Partial agonism means that even at maximal receptor occupancy, the maximal response (intrinsic efficacy ceiling) is less than that of a full agonist like morphine. Respiratory depression requires near-maximal mu receptor activation; because buprenorphine cannot produce maximal signaling regardless of dose, it plateaus below the threshold for clinically significant respiratory depression. However, at partial occupancy levels, the analgesic signal transduction pathway is still adequately activated, providing analgesia. Its very slow receptor dissociation kinetics (high receptor residence time) also contribute to its prolonged action.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.